FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942634811> ?p ?o ?g. }

• W2942634811 abstract "A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER⁺). PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER⁺ and/or progesterone receptor (PR)-positive (PR⁺) recurrent/metastatic gynecological cancers.Postmenopausal women with ER⁺ and/or PR⁺ ROC, who were asymptomatic and had cancer antigen 125 (CA125) progression after response to first line chemotherapy, where chemotherapy was not clinically indicated. Patients received anastrozole 1 mg daily until progression or unacceptable toxicity.Fifty-four patients were enrolled (52 evaluable). Clinical benefit at three months (primary endpoint) was observed in 18 patients (34.6%; 95% confidence interval [CI]=23%-48%). Median progression-free survival (PFS) was 2.7 months (95% CI=2.1-3.1). The median duration of clinical benefit was 6.5 months (95% CI=2.8-11.7). Most patients progressed within 6 months of starting anastrozole but 12 (22%) continued treatment for longer than 6 months. Anastrozole was well tolerated. In the exploratory analysis, ER histoscores and the intensity of ER staining did not correlate with clinical benefit rate or PFS.A subset of asymptomatic patients with ER⁺ and/or PR⁺ ROC and CA125 progression had durable clinical benefit on anastrozole, with acceptable toxicity. Anastrozole may delay symptomatic progression and the time to subsequent chemotherapy. The future challenge is to identify the subset of patients most likely to benefit from an aromatase inhibitor and whether the clinical benefit could be increased by the addition of other agents." @default.
• W2942634811 created "2019-05-09" @default.
• W2942634811 creator A5001026176 @default.
• W2942634811 creator A5008590899 @default.
• W2942634811 creator A5008960515 @default.
• W2942634811 creator A5018801649 @default.
• W2942634811 creator A5021894535 @default.
• W2942634811 creator A5023643377 @default.
• W2942634811 creator A5025018030 @default.
• W2942634811 creator A5035050460 @default.
• W2942634811 creator A5056466058 @default.
• W2942634811 creator A5062222799 @default.
• W2942634811 creator A5068472422 @default.
• W2942634811 creator A5077827698 @default.
• W2942634811 creator A5080422321 @default.
• W2942634811 date "2019-01-01" @default.
• W2942634811 modified "2023-10-17" @default.
• W2942634811 title "PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression" @default.
• W2942634811 cites W1817833980 @default.
• W2942634811 cites W1829801967 @default.
• W2942634811 cites W1918073772 @default.
• W2942634811 cites W1965392734 @default.
• W2942634811 cites W1969870046 @default.
• W2942634811 cites W1974841944 @default.
• W2942634811 cites W1987220103 @default.
• W2942634811 cites W1991318732 @default.
• W2942634811 cites W2002710053 @default.
• W2942634811 cites W2004615208 @default.
• W2942634811 cites W2009971333 @default.
• W2942634811 cites W2019607817 @default.
• W2942634811 cites W2020018978 @default.
• W2942634811 cites W2044497664 @default.
• W2942634811 cites W2044716671 @default.
• W2942634811 cites W2047880715 @default.
• W2942634811 cites W2076293231 @default.
• W2942634811 cites W2103607521 @default.
• W2942634811 cites W2115776903 @default.
• W2942634811 cites W2125498283 @default.
• W2942634811 cites W2128456807 @default.
• W2942634811 cites W2136759943 @default.
• W2942634811 cites W2147993322 @default.
• W2942634811 cites W2409054761 @default.
• W2942634811 cites W2552099557 @default.
• W2942634811 cites W2770938811 @default.
• W2942634811 doi "https://doi.org/10.3802/jgo.2019.30.e86" @default.
• W2942634811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6658604" @default.
• W2942634811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31328463" @default.
• W2942634811 hasPublicationYear "2019" @default.
• W2942634811 type Work @default.
• W2942634811 sameAs 2942634811 @default.
• W2942634811 citedByCount "17" @default.
• W2942634811 countsByYear W29426348112019 @default.
• W2942634811 countsByYear W29426348112020 @default.
• W2942634811 countsByYear W29426348112021 @default.
• W2942634811 countsByYear W29426348112022 @default.
• W2942634811 countsByYear W29426348112023 @default.
• W2942634811 crossrefType "journal-article" @default.
• W2942634811 hasAuthorship W2942634811A5001026176 @default.
• W2942634811 hasAuthorship W2942634811A5008590899 @default.
• W2942634811 hasAuthorship W2942634811A5008960515 @default.
• W2942634811 hasAuthorship W2942634811A5018801649 @default.
• W2942634811 hasAuthorship W2942634811A5021894535 @default.
• W2942634811 hasAuthorship W2942634811A5023643377 @default.
• W2942634811 hasAuthorship W2942634811A5025018030 @default.
• W2942634811 hasAuthorship W2942634811A5035050460 @default.
• W2942634811 hasAuthorship W2942634811A5056466058 @default.
• W2942634811 hasAuthorship W2942634811A5062222799 @default.
• W2942634811 hasAuthorship W2942634811A5068472422 @default.
• W2942634811 hasAuthorship W2942634811A5077827698 @default.
• W2942634811 hasAuthorship W2942634811A5080422321 @default.
• W2942634811 hasBestOaLocation W29426348111 @default.
• W2942634811 hasConcept C121608353 @default.
• W2942634811 hasConcept C126322002 @default.
• W2942634811 hasConcept C143998085 @default.
• W2942634811 hasConcept C203092338 @default.
• W2942634811 hasConcept C2775930923 @default.
• W2942634811 hasConcept C2776215463 @default.
• W2942634811 hasConcept C2776694085 @default.
• W2942634811 hasConcept C2777176818 @default.
• W2942634811 hasConcept C2777910003 @default.
• W2942634811 hasConcept C2778504769 @default.
• W2942634811 hasConcept C2780427987 @default.
• W2942634811 hasConcept C2780739268 @default.
• W2942634811 hasConcept C29456083 @default.
• W2942634811 hasConcept C31760486 @default.
• W2942634811 hasConcept C530470458 @default.
• W2942634811 hasConcept C535046627 @default.
• W2942634811 hasConcept C71924100 @default.
• W2942634811 hasConceptScore W2942634811C121608353 @default.
• W2942634811 hasConceptScore W2942634811C126322002 @default.
• W2942634811 hasConceptScore W2942634811C143998085 @default.
• W2942634811 hasConceptScore W2942634811C203092338 @default.
• W2942634811 hasConceptScore W2942634811C2775930923 @default.
• W2942634811 hasConceptScore W2942634811C2776215463 @default.
• W2942634811 hasConceptScore W2942634811C2776694085 @default.
• W2942634811 hasConceptScore W2942634811C2777176818 @default.
• W2942634811 hasConceptScore W2942634811C2777910003 @default.
• W2942634811 hasConceptScore W2942634811C2778504769 @default.
• W2942634811 hasConceptScore W2942634811C2780427987 @default.
• W2942634811 hasConceptScore W2942634811C2780739268 @default.

• next